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Abstract
Background: Success of cancer prodrugs relying on a foreign gene requires specific delivery of the gene to the
cancer, and improvements such as higher level gene transfer and expression. Attaining these objectives will be
facilitated in preclinical studies using our newly discovered CNOB-GDEPT, consisting of the produrg: 6-chloro-9-nitro-5-
oxo-5H-benzo-(a)-phenoxazine (CNOB) and its activating enzyme ChrR6, which generates the cytotoxic product 9-
amino-6-chloro-5H-benzo[a]phenoxazine-5-one (MCHB). MCHB is fluorescent and can be noninvasively imaged in mice,
and here we investigated whether MCHB fluorescence quantitatively reflects its concentration, as this would enhance
its reporter value in further development of the CNOB-GDEPT therapeutic regimen. PK parameters were estimated and
used to predict more effective CNOB administration schedules.
Methods: CNOB (3.3 mg/kg) was injected iv in mice implanted with humanized ChrR6 (HChrR6)-expressing 4T1
tumors. Fluorescence was imaged in live mice using IVIS Spectrum, and quantified by Living Image 3.2 software. MCHB
and CNOB were quantified also by LC/MS/MS analysis. We used non-compartmental model to estimate PK parameters.
Phoenix WinNonlin software was used for simulations to predict a more effective CNOB dosage regimen.
Results: CNOB administration significantly prolonged mice survival. MCHB fluorescence quantitatively reflected its
exposure levels to the tumor and the plasma, as verified by LC/MS/MS analysis at various time points, including at a
low concentration of 2 ng/g tumor. The LC/MS/MS data were used to estimate peak plasma concentrations, exposure
(AUC0-24), volume of distribution, clearance and half-life in plasma and the tumor. Simulations suggested that the
CNOB-GDEPT can be a successful therapy without large increases in the prodrug dosage.
Conclusion: MCHB fluorescence quantifies this drug, and CNOB can be effective at relatively low doses. MCHB
fluorescence characteristics will expedite further development of CNOB-GDEPT by, for example, facilitating specific
gene delivery to the tumor, its prolonged expression, as well as other attributes necessary for successful gene-delivered
enzyme prodrug therapy.
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Background
Cancer prodrugs are typically small molecules that are
essentially nontoxic but can be converted to a cytotoxic
compound (referred to from hereon as the “drug”) by
enzyme-catalyzed reactions [1]. A class of these (the “N-
prodrugs”) relies on enzymes native to humans, which
are expressed at a higher level in malignant compared to
normal cells. An example of this class is Mitomycin C
(MMC), which is reductively activated by nitroreduc-
tases, particularly the mammalian NQO1, whose con-
centration is up-regulated in cancer cells [2, 3], making
them more vulnerable to its action. However, as the nor-
mal cells also produce such enzymes, they too activate
MMC, resulting in serious off-target toxicity with this
and other N-prodrugs.
Another class of prodrugs (the “F-prodrugs”) requires
targeting to tumors of a foreign gene that encodes the
enzyme needed to generate the drug. This approach is
referred to as gene-delivered enzyme prodrug therapy
(GDEPT). It holds the promise of largely avoiding off-
target toxicity if the delivery of the gene and activation
of the prodrug are confined specifically to the tumor,
and considerable effort has been underway to develop
this therapeutic approach [4–7]. The prodrug Genciclo-
vir (GC), which is activated by the herpes simplex virus
1 thymidine kinase (TK1), was examined in a 4-year
Phase III clinical trial involving 248 glioblastoma multi-
forme patients [5]; and another prodrug, 5-aziridinyl-
2,4-dinitrobenzamide (CB1954), which requires the
Escherichia coli nitroreductase enzyme (NTR), is in clin-
ical trial for prostate cancer [8]. These studies have indi-
cated that the success of GDEPT depends, apart from
the obvious importance of specificity of gene delivery to
cancer, also on: a) high level gene transfer; b) extended
duration of gene expression; c) increasing the potency of
the activating enzyme; and d) an efficient bystander effect
(BE). (BE refers to the spread of the activated drug from
the transformed cells capable of producing it to the neigh-
boring cells lacking this capacity, and is critical to the effi-
cacy of any GDEPT therapy because no method of gene
delivery can transform all the cancer cells in a tumor.)
Attaining these objectives would be facilitated by a
prodrug regimen whose drug product could be visual-
ized non-invasively in living mice, as the resulting
‘observational approach’ would minimize the need for
mouse sacrifice and the use of more involved tests,
such as LC/MS/MS; native fluorescence in a drug is
also superior to attaching a fluorophore to visualize
it, as the fluorophore may affect the drug in unpre-
dictable ways [9].
We have previously reported the discovery of such a
regimen [10, 11], consisting of the prodrug 6-chloro-9-
nitro-5-oxo-5H-benzo-(a)-phenoxazine (CNOB), and the
newly discovered bacterial nitroreductase (also referred
to as chromate reductase), ChrR. We have improved the
latter several-fold, generating ChrR6 and its humanized
version HChrR6 [12, 13]. The activated cytotoxic prod-
uct of CNOB, 9-amino-6-chloro-5H-benzo[a]phenoxa-
zine-5-one (MCHB), is fluorescent and has been
successfully visualized non-invasively in living mice; this
is illustrated in Additional file 1: Figure S1 (reproduced
from reference [11] for convenience). The figure shows
that in tumors producing ChrR6, MCHB is visible fol-
lowing iv CNOB injection, but not in tumors lacking
ChrR6 [11]. The CNOB/ChrR6 regimen (referred to
from hereon as ‘CNOB-GDEPT’) is effective not only in
killing several different cancer cell lines in vitro, but also
in treating implanted 4T1 murine mammary tumors in
mice with 40 % complete survival on day 140 (10 mg/kg
CNOB administered in three daily doses of 3.3 mg/kg);
all the untreated mice in this study were dead by day 25
[11]. These 4T1 tumors represent human stage IV breast
cancer model, reflective of both disease progression and
metastatic characteristics [14]. CNOB alone, even at
high concentrations (up to 20 mg/kg), showed no signifi-
cant toxicity, as determined by blood chemistry panel
values. MCHB has an impressive BE and kills cells by
intercalating with mitochondrial DNA, causing apoptosis
involving the mitochondrial pathway, and likely kills
both growing and non-growing cells [11].
Our previous work established that CNOB fluores-
cence indicated its presence, but to what degree the
fluorescence represented MCHB quantity was not ad-
dressed. As quantitative representation of MCHB by its
fluorescence would enhance its utility in preclinical
studies, we have investigated this here. We report that
MCHB fluorescence does quantitatively correspond to
its concentration; we also provide information on as-
pects of the pharmacokinetics (PK) of the CNOB-
GDEPT and predictions on more effective CNOB
dosages.
Methods
Construction of 4T1/HChrR6 cells
4T1 cells (ATCC) were transfected with humanized
chrR6 (HchrR6) gene using Sleeping Beauty transposon
method as described before [11]. Briefly, HchrR6 gene
was cloned into pKT2/UXbG using HindIII/ApaI restric-
tion sites, creating pKT2/hU-HchrR6-SN. Cells were
grown to 90–95 % confluence in DMEM without antibi-
otics in a six-well plate. Transposase vector (pUb-SB11;
0.8 μg) and transposon DNA (pKT2/hU-HchrR-SN and
pKT2/BGL; 7.2 μg) were added to 0.5 mL Opti-MEM
(Invitrogen). In another vial, 20 μL of Lipofectamine
2000 (Invitrogen) were added to 0.5 mL of Opti-MEM,
and incubated at room temperature (5 min). The
medium was aspirated and cells were washed once with
PBS. The above solutions were combined, added to each
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well (total of 1 mL/well), and incubated for 18 to 24 h.
The transfection solution was then aspirated and re-
placed by complete DMEM. Cells were incubated for an
additional 48 h and selected with geneticin (Invitrogen;
2 mg/mL; this concentration was predetermined as the
minimal killing dose for 4T1 cells). To ensure homogen-
eity of HchrR6 expression, cells expressing luciferase
were diluted to ~30 cells per 10 mL DMEM, supple-
mented with geneticin, and 100 μL aliquots were dis-
pensed into a 96-well plate. This dilution generates a
~30 % probability of a well receiving a single cell, so that
colonies in a well would develop from a single cell.
In vitro cell viability and fluorescence assays
4T1 cells transfected to constitutively express HChrR6
(‘4T1/HChrR6’ cells) were incubated (37 °C) with 15 μM
CNOB for the specified time periods. MCHB fluorescence
was measured as described below. Viability was deter-
mined at corresponding time periods by the MTS assay.
In vivo studies
Female nude (nu/nu) mice were inoculated subcutane-
ously in mammary fat pad number 9 with 4T1/HChrR6
cells, i.e., cells endogenously generating HChrR6 (1 ×
106 cells in 50 % PBS/50 % matrigel). Tumors were
allowed to grow for 10-14 days before injecting CNOB
(3.3 mg/Kg) and subsequent imaging and fluorescence-
or LC/MS/MS-based quantification of MCHB. To
minimize background fluorescence, mice were fed puri-
fied rodent diet (AIG093, Dyets Inc.). Tumor burden
was measured by caliper.
For detecting off-target activation of CNOB, firefly lu-
ciferase (F-Luc)-expressing untransfected 4T1 cells (not
generating HChrR6) were used for tumor implantation
and the tumors were visualized and imaged 5 min after
intraperitoneal (ip) injection of luciferin (150 μL of
30 mg/mL solution); the (luc promoter-controled) chrR6
gene was delivered using SL7838-chrR6 bacteria [11, 15];
the bacteria contained the Lux operon, permitting their
visualization, as before [11]. The bacteria were treated
with IPTG to induce the enzyme before tail vain
injection.
Imaging
Ninety-six-well black color plates with transparent bot-
tom (Costar) and a plate reader (SpectraMax, Molecular
Devices) were used for in vitro fluorescence imaging.
For in vivo experiments, mice carrying 4T1 tumors were
injected with CNOB (3.3 mg/kg iv) prior to imaging.
The images were acquired by IVIS Spectrum (Perkin
Elmer Inc.) and quantified by Living Image 3.2 software
(Perkin Elmer Inc.). The exposure time for photography
was 1 s. A standard curve was constructed in vitro based
on the quantified photon intensity at various MCHB
concentrations (0, 1.5, 15, 150, 1500 μM). Biolumines-
cence was measured using the same instrument. We
note that the IVIS instrument is widely used for quanti-
tative fluorescence/bioluminance imaging, as it possesses
a built-in calibration system. As already stated, this per-
mitted generation of a standard curve that linearly re-
lated MCHB photon yield with its concentration. The
imaging experiments were performed at least four times.
LC/MS/MS analysis
Tumor tissue was weighed and homogenized (using 3x
volume of PBS/unit weight) using Pro250 homogenizer
(Pro Scientific Inc.). For the preparation of standards,
various freshly prepared CNOB/MCHB combinations (0,
0.25, 0.5, 1, 2, 2.5, 5, 10, and 20 ng of each) were mixed
either with 0.2 mL of blank tumor homogenate, or
spiked to the blank plasma. All samples were further
spiked with 25 μL of fresh internal standard (Chem-
bridge ID 6066331) plus 10 μL of NH4OH (100 mM),
and extracted in 2 mL of ethyl acetate (vortexing and
centrifugation at 1400 × g for 10 min). Samples in ethyl
acetate phase were evaporated and re-constituted in
acetonitrile for LC/MS/MS analysis. Compounds were
separated and quantified by the Micromass Quattro
Premier triple quadrupole HPLC-MS by experts at Stan-
ford University Mass Spectrometry Lab. The extraction
efficiency was 95-99 %. Samples were stored at -80 °C and
the LC/MS/MS analysis was performed within 2 weeks;
CNOB and MCHB remained stable during this time.
Prediction of alternate modes of administration and
statistical analysis
The Phoenix WinNonlin software (version 6.3, Certara,
Princeton, NJ) was used to make projections using the
PK data obtained here for predicting a potentially more
effective dosage regimen of CNOB-GDEPT. All data
were calculated and analyzed by the GraphPad Prism
software. Statistics were determined using Student’s t-
test and correlation analysis; p values of less than 0.05
were considered significant.
The statistical analysis of the AUC data (Table 1)
was done by log-transformed raw AUC data, followed
by two-tail paired t-test between groups of two tumor
types. The log transformation gives more normally
distributed data that better fit the assumptions of the
t-test. This method is recommended by the US FDA
for analyzing AUC of bioequivalent drugs. The reason
the t-test instead of the z-test (as done for most bioequiva-
lent studies) was used is because of the sample size (<30).
Results
Noninvasive visualization of off-target CNOB activation
In our previous work (Additional file 1: Figure S1), acti-
vation of CNOB was confined to the implanted
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breast tumor by injecting ChrR6-generating SL7838 bac-
teria directly into the tumor. To determine if MCHB
fluorescence can permit non-invasive imaging of off-
target activation of CNOB, we used similar breast tumor
implants and supplied the (lac promoter-controlled)-
chrR6 gene for CNOB activation using the above-
mentioned ChrR6-generating bacteria injected via the
tail vein. We have previously shown that although six
days following such injection, bacteria localize exclu-
sively in the tumors, they initially colonize other organs
as well [11, 15]. At 24 h, the SL7838 bacteria, visualized
by Lux expression, did indeed show a wide distribution
but with concentration in kidneys and the tumor; MCHB
could be non-invasively visualized at both sites (Fig. 1).
Quantitative nature of MCHB fluorescence
In addressing this, we first examined if CNOB, having a
nitro-substituted benzene ring, is itself fluorescent and
thus might interfere with MCHB fluorescence. (CNOB
and other compounds studied here were dissolved in
DMSO at 15 μM concentration.) CNOB is indeed fluor-
escent, but its fluorescence properties are distinct from
MCHB in both excitation and emission wavelengths:
570/620 nm for MCHB vs. 500/560 nm for CNOB; fur-
thermore, CNOB fluorescence is much weaker than of
MCHB, and at the peak emission wavelength of MCHB,
CNOB fluorescence is negligible (Fig. 2). Doxorubicin, a
widely used and well characterized anticancer drug, is
also fluorescent and this property has facilitated its PK
and other studies [16–20]. We found that MCHB gener-
ates over 15-fold greater number of photons than Doxo-
rubicin (Fig. 2), making its fluorescence an important
asset in characterizing and enhancing its therapeutic
potential.
That MCHB fluorescence might represent a quantita-
tive measure of this drug was first suggested by in vitro
studies. CNOB was added to transfected 4T1 cells en-
dogenously expressing HChrR6, and cell killing and
MCHB fluorescence were measured. A direct correcla-
tion was found between the fluorescence intensity and
cell killing kinetics (Fig. 3).
To test if this might be the case also in vivo, orthoto-
pic tumors were implanted using transfected 4T1 cells
(endogenously expressing HChrR6) on mammary fat
pad number 9 of mice, and CNOB (3.3 mg/kg) was
injected via the tail vein. MCHB fluorescence was im-
aged in live mice (n = 4) and converted to its concentra-
tion using the standard curve mentioned in Materials
and Methods (Fig. 4a). MCHB fluorescence could be im-
aged in the tumors as early as 5 min after CNOB injec-
tion, reaching a peak concentration of ca. 50 ng/g tumor
at 15 min; at 24 h, the concentration had gone down to
some 2 ng/g tumor, which could still be successfully im-
aged; the baseline count values were consistent overtime.
(Note that fluorescence in the 12 and 24 h images is not
evident to the naked eye but is recorded by the camera,
being 33,700 ± 11,996 and 8,520 ± 1,698 counts/s, re-
spectively). In another set of animals, MCHB in the tu-
mors was measured by postmortem LC/MS/MS analysis
(n = 4) at each of the above time points (Fig. 4a). Al-
though this comparison involved separate sets of tumors
in different mice, it is evident that the two methods
nevertheless gave similar results: correlation analysis
gave Pearson’s r value of 0.986 (p < 0.01; Fig. 4b).
Analogous experiments indicated that in plasma as well,
imaging and LC/MS/MS analyses give similar results for
MCHB concentration (Additional file 1: Figure S2). The
results support the conclusion that measuring MCHB
concentrations by fluorescence and LC/MS/MS give very
similar values.
Tumor PK measurements
Based on FDA recommendations [21], the PK parame-
ters were analyzed at the single dose used above
(3.3 mg/kg). Area under the tumor concentration curve
(AUC) over the 24 h time course (AUC0-24) was calcu-
lated using the trapezoidal rule from the results of each
MCHB measurement method from the data of Fig. 4a.
Similar results were obtained: 325 ± 121 (h•ng/g) for LC/
MS/MS and 336 ± 183 (h•ng/g) for imaging (Table 1).
As noted above, several nitroreductases, including the
mammalian NQO1, are upregulated in cancer cells [2, 3]
Fig. 1 Detection of off-target activation of CNOB by non-invasive imaging. Tumors were implanted in mice using F-Luc expressing non-
transfected breast cancer cells that did not generate HChrR6, and the HchrR6 gene was delivered via SL7838-chrR6 bacteria (tail vein injection).
Right, center and left pictures show, respectively: the tumor location imaged 5 min after ip injection of luciferin (150 μL of 30 mg/mL); the loca-
tion of SL7838-chrR6 bacteria in the mice 24 h post iv injection visualized by their Lux expression; and the location of MCHB generation imaged
8 h post tail vein CNOB injection
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Fig. 2 Fluorescence intensity of CNOB, MCHB and Doxorubicin. a Photon yields of CNOB (excitation/emission, 500/560 nm), MCHB (570/620 nm)
and Doxorubicin (500/560 nm); all drugs were dissolved in DMSO at 15 μM concentration. b At MCHB fluorescence regimen (570/620 nm), CNOB
fluorescence is negligible and thus does not interfere with fluorescence-based assessment of MCHB levels. The right bar indicates fluorescence
intensity
Fig. 3 Correlation between MCHB fluorescence and cell killing in vitro. a MCHB fluorescence [relative units (RFU)] is shown in relation to loss of
cell viability with time after CNOB (15 μM) addition to 4T1 cells constitutively generating HChrR6. Nonlinear regression was used for curve fitting.
Error bars represent standard deviation (SD; n = 4). b Using GraphPad Prism software, correlation between viability and fluorescence (RFU) at each
time point was calculated and is presented as Pearson’s r value and probability of correlation (p value)
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and our finding that CNOB alone has little anticancer
effectiveness in mice [11] suggests that these enzyme
levels must be ineffectual in activating this prodrug for
treatment purposes. To gain an idea of these levels, we
measured MCHB generation in ‘naïve’ tumors (i.e.,
tumors not generating HChrR6), using both fluores-
cence- and LC/MS/MS-based quantification methods.
These tumors did generate MCHB, but to an AUC0-24
which was some six-fold less than the transfected tu-
mors (Table 1). As no curative effect of CNOB was seen
in mice implanted with the naïve 4T1 tumors (the sur-
vival was equal to PBS injection) – the AUC0-24 expos-
ure levels of the naïve and tranfected tumors bracket the
non-curative and significantly curative MCHB levels: the
survival of mice with transfected tumors at this dose in-
creased by 45 days [11]. The results of Table 1 again
show that MCHB quantification by imaging and LC/
MS/MS give similar values.
Plasma PK measurements
Plasma PK parameters were estimated ex vivo for
both MCHB and CNOB by LC/MS/MS analysis
(Fig. 5). The data were analyzed using non-
compartmental model (Table 2). Peak plasma concen-
trations (Cmax), and exposure (AUC0-24), were similar
for CNOB and MCHB. Volume of distribution was
estimated to be high for both CNOB and MCHB at
81.5 and 117 L/kg, respectively, suggesting extensive
extravascular distribution, which agrees with previous
findings [11]. As regards the terminal phase parame-
ters, the clearance (CL) values were similar, and al-
though the half-life tended to be different (t1/2:
CNOB 4.6 h, MCHB 8.3 h), both were in the shorter
range. It should be noted that the MCHB parameter
estimates are influenced by the kinetics of CNOB
conversion to MCHB. Although the densities of the
tumors and plasma differ, it is apparent in comparing
AUC values that there was a considerably greater
amount of tumor exposure to MCHB, which is con-
sistent with the curative effect at this CNOB dose
mentioned above.
Prediction of a more effective dosage regime
In further preclinical studies, we are currently attempt-
ing to use extracellular vesicles (also referred to as exo-
somes [22]) to specifically deliver CNOB activating
capacity to HER2 +ve breast cancer and to develop a
Fig. 4 Quantification of MCHB in 4T1 tumors by imaging and LC/
MS/MS. a The upper left encircled figure focuses on changes within
the first two hours. Representative tumor images (above the curves)
at the indicated time points illustrate the change in MCHB
fluorescence, which was used to calculate MCHB concentration
using a standard curve. (Fluorescence in the 12 and 24 h images is
not evident to the naked eye but is recorded by the camera; see
text for further details. At 24 h, the concentration of MCHB is
extremely low, which accounts for the high variance at this time
point; at other time points, the variance is markedly lower). b
Correlation analysis of the two measurements: Pearson’s r = 0.99,
p < 0.0001
Table 1 MCHB AUC in untransformed and HchrR6-transformed
4T1 tumors. AUC values in tumors were calculated over 24 h of
CNOB treatment as determined by fluorescence imaging and
LC/MS/MS. Statistical analysis of AUC was carried out by log
transformed raw AUC data followed by two-tail paired t-test
between each two groups of samples
AUC (h*ng/g tissue) Imaging LC/MS/MS
4T1 54 ± 34 50 ± 28
4T1/HchrR6 336 ± 183** 325 ± 121**
** p < 0.01 as compared between 4T1 and 4T1/HchrR6 tumors using the same
quantitative approach; no significant difference was observed between groups
with the same type of tumors
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more curative therapeutic regimen. These studies would
be facilitated by guidance on alternate doses/administra-
tion schedules of CNOB that may enhance its thera-
peutic efficacy.
This analysis required assumption of PK linearity. We
reasoned that this assumption was justified given the fol-
lowing facts. The in vivo activation of CNOB into
MCHB took place within a very short time (five minutes;
Fig. 4); the same was the case with its clearance, since
we could detect MCHB in urine and feces of the mice
within 15 min of CNOB injection (data not shown), and
little MCHB could be detected in the tumor by 24 h
(Fig. 4). The PK profile of both CNOB and MCHB in
the plasma was also very rapid as neither compound
remained in the plasma by 24 h. Therefore, at our mul-
tiple dosing schedule of 48 h, the clearance from the
previous dose was complete.
Using the PK parameters estimated above for the sin-
gle (3.3 mg/kg) dose as starting point, tumor growth kin-
etics at the dosage regime used in our previous study
(10 mg/kg total, administered in three daily doses of
3.3 mg/kg [11]; Fig. 6), and assuming PK linearity as
mentioned above, we constructed a combined PK/PD
model. Non-compartment PK parameters were used as
initial estimates in the combined PK/PD model, which
includes a two compartment iv (PK) model linked
with an inhibitory Emax (PD) model. Figure 7 shows
the predicted plasma CNOB concentrations (a) and
corresponding tumor growth curves (b) after
Fig. 5 Plasma levels of MCHB and CNOB in mice bearing 4T1
orthotopic tumors expressing HChrR6. The upper left encircled
figure focuses on changes within the first two hours. Following tail
vein CNOB injection plasma was harvested at various time points.
Plasma levels of MCHB and CNOB were quantified by LC/MS/MS.
The lower figure provides values up to the time points where the
concentration of the compounds could be reliably measured. Note
that the CNOB and MCHB concentrations are shown as touching the
abscissa; this is because the measured quantities at 24-h time point
were below the detection limit of the instrument (We did obtain the
LC/MS/MS quantification data for the 24-h time point. But since it
was below the instrument’s quantification limit). Plasma was collected
at indicated times after CNOB injection (3.3 mg/kg). Data represent
average of samples at each time point (n= 4). See text for further details
Table 2 Plasma pharmacokinetic parameters of MCHB and
CNOB in mice carrying 4T1/HchrR6 tumors. Plasma samples
were collected at various times (5 min, 15 min, 30 min, 1 h, 2 h,
4 h, 6 h, 12 h, and 24 h) after iv dose of CNOB in nude mice
carrying 4T1/HchrR6 tumors. MCHB and CNOB levels overtime
were determined by LC/MS/MS
CNOB Dose Analyte Cmax ± SE AUC0-24 ± SE Vss CL t1/2
mg/kg ng/mL h*ng/mL L/kg L/h/kg h
3.3 CNOB 141 ± 28.6 166 ± 23.5 81.5 17.7 4.6
MCHB 145 ± 30.4 148 ± 16.0 117 21.1 8.3
Cmax maximum observed concentration ± standard error (SE), AUC0-24 area
under the concentration curve from 0 to 24 h ± SE, Vss volume of distribution,
CL clearance; t1/2 terminal elimination half-life
Fig. 6 Tumor burden in implanted 4T1 murine mammary tumors
following CNOB administration via tail vein. ChrR6 was delivered iv
using SL7838 bacteria carrying the gene encoding this enzyme,
controlled by the lac promoter; IPTG was used when activation of
the gene was required. Tumor burden was measured on the
indicated days following CNOB injection (10 mg/kg in three 3.3 mg/
kg daily doses). Data represent mean value ± standard deviation (SD)
(n = 5). See Figure for the symbols
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simulation of 3.3, 10, and 20 mg/kg of CNOB given
daily for 3 days. Based on the tumor growth curves,
these simulations suggest that increasing doses of
CNOB may have notable effects on tumor progres-
sion, and large increases in CNOB dosage may not be
required for successful therapy.
Discussion
The fluorescence of CNOB is negligible at the emission
wavelength of MCHB, meaning that the fluorescence
thus measured is that of MCHB alone. Further, measure-
ments of MCHB concentration by its fluorescence and
by LC/MS/MS gave similar results. This was shown in
vitro by cell killing kinetics, and in vivo for both trans-
fected and untransfected implanted 4T1 tumors (with
and without endogenous HChrR6 expression) down to
MCHB levels of 2 ng/g tumor, as well as for the plasma.
We conclude that the non-invasive MCHB fluorescence
imaging is a reliable indicator of its concentration.
As mentioned in the Background, certain conditions
must be met for successful development of an F-prodrug
regimen, and the fluorescence characteristics identified
here provide a powerful tool for attaining these condi-
tions for the CNOB-GDEPT. Two examples will suffice
to highlight the importance of this tool in this context.
First, to attain specific targeting that confines the
CNOB-activating capability to the tumor would require
testing a variety of methods involving the use, for in-
stance, of different delivery vehicles, and targeting li-
gands for a given cancer. As Additional file 1: Figures S1
and S2 illustrate, noninvasive imaging of MCHB fluores-
cence in living mice can provide a rapid screen of the
relative success of methods differing in these, as well as
other aspects, that may need to be tested for specific
targeting of the tumor. Of course, final confirmation will
necessitate the use of ex-situ and more robust methods,
such as LC/MS/MS, immunohistochemical, Western
and others, but a quick initial ‘observational’ screen will
greatly narrow the outcomes that would require the use
of these involved and labor intensive techniques.
The second example that illustrates the advantage of
MCHB fluorescence concerns the fact that gene expres-
sion has proved a limiting factor in the success of F-
prodrug therapy (Background). Several different ap-
proaches would need to be tested to address this prob-
lem. Although DNA has been primarily used in gene
delivery, there may be compelling advantages in using
mRNA instead. For DNA-mediated gene delivery, trans-
port into the nucleus is required for expression, and It is
well established that DNA transport to the nucleus is
highly inefficient [23, 24]; in contrast, mRNA expression
can occur directly in the cytosol. Studies have indeed
shown the superiority of mRNA over DNA in gene
transfer in both proliferating and non-proliferating cells
[25, 26]. Direct protein transfer may also need to be con-
sidered along with measures to enhance the stability and
duration of expression. As is seen in Fig. 4, the relative
effectiveness of these approaches in improving the level
and duration of expression of the gene (or mRNA) and
its peak levels can also be quickly gauged with this pro-
drug regimen by imaging, minimizing the need for the
ex situ involved techniques. Visualization approaches
can also be applied to rapidly assess the extent of trans-
fection of cells in tumors to generate the bystander ef-
fect required for effective therapy.
The PK parameters measured here enabled us to pre-
dict ways of administering CNOB to make the therapy
more effective. This information will aid in the clinical
Fig. 7 Simulation of CNOB dose administrations and predicted tumor growth inhibition. Based on the PK parameters estimates from
noncompartmental analysis of single (3.3 mg/kg) dose of CNOB, and tumor growth data (Fig. 6), a combined PK/PD model was constructed
which included a 2 compartment iv model linked with an inhibitory Emax model. Simulation predicted plasma CNOB concentrations (a) and
corresponding tumor growth curves (b) after the indicated daily doses of CNOB. Circles represent original tumor burden data from Fig. 6
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transfer of this regimen. Indeed, we have already suc-
ceeded in specific delivery of ChrR6 mRNA to the
HER2 +ve BT474 cells conferring on them the capacity
to convert CNOB into MCHB (ms in preparation). Fur-
ther studies for transfer to the clinic of the exosome-
based regimen will utilize more sophisticated PK/PD
models, for example that developed by Simeoni et al
(http://www.ncbi.nlm.nih.gov/pubmed/14871843) to link
plasma concentration over time data to tumor growth.
Conclusion
The fluorescence intensity of the cytotoxic product of
CNOB-GDEPT, MCHB, quantitatively reflects its expos-
ure level in the tumor and plasma. This feature provides
a powerful tool to rapidly screen a variety of approaches
to make this regimen a successful anticancer therapy; it
permits noninvasive imaging of MCHB generation in
live mice, thereby greatly narrowing the outcomes that
would need to be followed up by the use of more rigor-
ous but also more labor intensive approaches. The pre-
diction of a more optimal dose regimen of CNOB
reported here will also facilitate attaining this end.
Additional file
Additional file 1: Figure S1. Visualization of MCHB generation in living
mice by fluorescence imaging. Following CNOB administration, MCHB
fluorescence was visualized by imaging in implanted murine mammary
tumors expressing firefly luciferase (F-Luc; for bioluminescent imaging);
ChrR6 was delivered intratumorally using bacteria carrying the gene
encoding this enzyme and expressing Lux to visualize them. (The Luc
signal includes Lux, but because the former was >50-fold greater, the
latter is negligible.) IVIS (bioluminescence) and Maestro (fluorescence)
systems were used in imaging. Reproduced from our previous work [11]
for ease of reference. Figure S2. Correlation between plasma MCHB
levels determined by fluorescence and LC/MS/MS measurements. MCHB
was measured in the plasma of mice bearing implanted 4T1 tumors
expressing HChrR6 by fluorescence imaging or LC/MS/MS at selected
time intervals following tail vein injection with CNOB (3.3 mg/kg).
Quantification was done as described in Materials and Methods. Statistical
analysis was performed using GraphPad Prism. (DOCX 536 kb)
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